3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1
6
Phase 3
3
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Tumor-Agnostic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
11
Prostatic Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Carcinoma
3
Pain
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Medullary
2
Carcinoma, Hepatocellular
2
von Hippel-Lindau Disease
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenoma, Islet Cell
1
Adenocarcinoma, Follicular
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
cabozantinib
×
Clear all
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts